Pipeline

Overview

Product Pipeline

Research
Pre Clinical
Phase 1/2
Phase 2
Phase 3
Hemostasis
SQ Marzeptacog alfa (activated) "MarzAA”
Hemophilia A or B with inhibitors – ToB
R
PC
P1/2
P2
P3
SQ Marzeptacog alfa (activated) "MarzAA”
Hemophilia A or B with inhibitors – ToB
FVIID/Glanzmann/Hemlibra – ToB
R
PC
P1/2
P2
P3
FVIID/Glanzmann/Hemlibra – ToB
Complement
R
PC
P1/2
P2
P3
SQ CB 4332
Enhanced CFI (ConFIrm)*
R
PC
P1/2
P2
P3
SQ CB 4332
Enhanced CFI (ConFIrm)*
C3b/C4b degraders
R
PC
P1/2
P2
P3
C3b/C4b degraders
C3a/C5a degraders
R
PC
P1/2
P2
P3
C3a/C5a degraders
Hemostasis
SQ Dalcinonacog alfa (FIX) "DalcA”
Hemophilia B
R
PC
P1/2
P2
P3
SQ Dalcinonacog alfa (FIX) "DalcA”
Hemophilia B
CB 2679d-GT
Hemophilia B FIX gene therapy
R
PC
P1/2
P2
P3
CB 2679d-GT
Hemophilia B FIX gene therapy

*Screening study ongoing

X